Tiny Stock Taking on Big Pharma
Big Pharma doesn't want to CURE depression. The longer we stay depressed, the more money they make. But one new company is changing all that.
And it's not too late to capitalize today

GSK Insider Trading (GlaxoSmithKline)

Insider Ownership Percentage: N/A
Insider Buying (Last 12 Months): £44,271,726.03
Insider Selling (Last 12 Months): £391,710.06

GlaxoSmithKline Insider Trading History Chart

This chart shows the insider buying and selling history at GlaxoSmithKline by year and by quarter.

Skip ChartChart Data in Insider Trading History Table

GlaxoSmithKline Share Price & Price History

Current Price: GBX 1,406.20
Price Change: Price Decrease of -3 (-0.21%)
As of 06/24/2021 05:45 PM ET

This chart shows the closing price history over time for GSK up to the past year.

Skip Chart and Table DataPrice Data in Insider Trading History Table
Days: 30 | 90 | 365
Why Are Billionaire Investors Betting On The 2021 Mental Health Revolution?
Investors say this little-known sector feels exactly like CBD did in 2017. This new technology is making investors like Peter Thiel very excited.
See How Early "Mental Health Revolution" Investors

GlaxoSmithKline Insider Trading History

Transaction DateInsider NameTitleBuy/SellNumber of SharesAverage Share PriceTotal TransactionShares Held After TransactionDetails
5/12/2021Emma WalmsleyInsiderBuy10GBX 1,341£134.10
4/28/2021Urs RohnerInsiderBuy629GBX 1,340£8,428.60
4/13/2021Emma WalmsleyInsiderBuy9GBX 1,291£116.19
3/1/2021Emma WalmsleyInsiderSell32,346GBX 1,211£391,710.06
2/9/2021Emma WalmsleyInsiderBuy10GBX 1,272£127.20
2/3/2021Urs RohnerInsiderBuy619GBX 1,361£8,424.59
1/12/2021Emma WalmsleyInsiderBuy9GBX 1,384£124.56
12/30/2020Manvinder Singh BangaInsiderBuy36,600GBX 1,376£503,616
12/9/2020Emma WalmsleyInsiderBuy9GBX 1,403£126.27
11/10/2020Emma WalmsleyInsiderBuy9GBX 1,462£131.58
10/28/2020Jonathan SymondsInsiderBuy3,240,741GBX 1,350£43,750,003.50
10/9/2020Emma WalmsleyInsiderBuy8GBX 1,440£115.20
9/10/2020Emma WalmsleyInsiderBuy8GBX 1,520£121.60
8/11/2020Emma WalmsleyInsiderBuy8GBX 1,598£127.84
7/9/2020Emma WalmsleyInsiderBuy8GBX 1,610£128.80
5/12/2020Emma WalmsleyInsiderBuy7GBX 1,693£118.51
4/9/2020Emma WalmsleyInsiderBuy28GBX 1,536£430.08
3/10/2020Emma WalmsleyInsiderBuy8GBX 1,569£125.52
2/17/2020Emma WalmsleyInsiderSell11,680GBX 1,661£194,004.80
2/11/2020Emma WalmsleyInsiderBuy7GBX 1,726£120.82
2/5/2020Judy LewentInsiderBuy788GBX 2,344£18,470.72
1/10/2020Emma WalmsleyInsiderBuy7GBX 1,800£126
12/10/2019Emma WalmsleyInsiderBuy8GBX 1,731£138.48
11/11/2019Emma WalmsleyInsiderBuy7GBX 1,727£120.89
10/30/2019Vivienne CoxInsiderBuy308GBX 1,725£5,313
10/9/2019Emma WalmsleyInsiderBuy7GBX 1,729£121.03
9/10/2019Emma WalmsleyInsiderBuy8GBX 1,658£132.64
8/9/2019Emma WalmsleyInsiderBuy7GBX 1,674£117.18
7/24/2019Vivienne CoxInsiderBuy434GBX 1,654£7,178.36
7/9/2019Emma WalmsleyInsiderBuy8GBX 1,636£130.88
6/11/2019Emma WalmsleyInsiderBuy7GBX 1,585£110.95
5/10/2019Emma WalmsleyInsiderBuy9GBX 1,512£136.08
5/1/2019Manvinder Singh BangaInsiderBuy458GBX 1,568£7,181.44
2/18/2019Emma WalmsleyInsiderSell9,053GBX 1,576£142,675.28
2/15/2019Emma WalmsleyInsiderSell66,159GBX 1,585£1,048,620.15
2/13/2019Victoria WhyteInsiderBuy3,020GBX 1,547£46,719.40
2/11/2019Simon DingemansInsiderBuy8GBX 1,554£124.32
2/6/2019Jesse GoodmanInsiderBuy845GBX 1,964£16,595.80
1/10/2019Emma WalmsleyInsiderBuy8GBX 1,524£121.92
12/11/2018Emma WalmsleyInsiderBuy8GBX 1,494£119.52
11/9/2018Simon DingemansInsiderBuy8GBX 1,561£124.88
10/9/2018Simon DingemansInsiderBuy9GBX 1,475£132.75
9/11/2018Victoria WhyteInsiderBuy8GBX 1,497£119.76
8/9/2018Emma WalmsleyInsiderBuy8GBX 1,593£127.44
7/31/2018David RedfernInsiderSell1,925GBX 1,575£30,318.75
7/25/2018Philip R HamptonInsiderBuy2,810GBX 1,557£43,751.70
7/10/2018David RedfernInsiderBuy8GBX 1,564£125.12
See Full Table
Insider Trading at GlaxoSmithKline?
Sign-up to receive InsiderTrades.com's daily insider buying and selling report for GlaxoSmithKline and related companies.

SEC Filings (Institutional Ownership Changes) for GlaxoSmithKline (LON:GSK)

GlaxoSmithKline logo
GlaxoSmithKline plc, together with its subsidiaries, engages in the creation, discovery, development, manufacture, and marketing of pharmaceutical products, vaccines, over-the-counter medicines, and health-related consumer products in the United Kingdom, the United States, and internationally. It operates through four segments: Pharmaceuticals, Pharmaceuticals R&D, Vaccines, and Consumer Healthcare. The company offers pharmaceutical products comprising medicines in the therapeutic areas, such as respiratory, HIV, immuno-inflammation, oncology, anti-viral, central nervous system, cardiovascular and urogenital, metabolic, anti-bacterial, and dermatology. It also provides consumer healthcare products in wellness, oral health, nutrition, and skin health categories. The company offers its consumer healthcare products in the form of nasal sprays, tablets, syrups, lozenges, gum and trans-dermal patches, caplets, infant syrup drops, liquid filled suspension, wipes, gels, effervescents, toothpastes, toothbrushes, mouthwashes, denture adhesives and cleansers, topical creams and non-medicated patches, lip balm, gummies, and soft chews. It has collaboration agreements with 23andMe; Lyell Immunopharma, Inc.; Novartis; Sanofi SA; Surface Oncology; Progentec Diagnostics, Inc., and CureVac AG., as well as strategic partnership with IDEAYA Biosciences, Inc. and Vir Biotechnology, Inc. GlaxoSmithKline plc was founded in 1715 and is headquartered in Brentford, the United Kingdom.
Read More on GlaxoSmithKline

Today's Range

Now: GBX 1,406.20
Low: 1,401.20
High: 1,417.60

50 Day Range

MA: GBX 1,361.51
Low: 1,325.20
High: 1,437.80

52 Week Range

Now: GBX 1,406.20
Low: 1,190.80
High: 1,671.60

Volume

10,152,067 shs

Average Volume

8,121,937 shs

Market Capitalization

£70.75 billion

P/E Ratio

13.50

Dividend Yield

5.74%

Beta

N/A

Who are the company insiders with the largest holdings of GlaxoSmithKline?

GlaxoSmithKline's top insider shareholders include:
  1. Emma Walmsley (Insider)
  2. Jonathan Symonds (Insider)
  3. Judy Lewent (Insider)
  4. Manvinder Singh Banga (Insider)
  5. Urs Rohner (Insider)
  6. Vivienne Cox (Insider)
Tiny Stock Taking on Big Pharma
Big Pharma doesn't want to CURE depression. The longer we stay depressed, the more money they make. But one new company is changing all that.
And it's not too late to capitalize today